1月. 04, 2019

Novopyxis – The first start-up identified by LEO Science & Tech Hub

LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin.

The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an autoimmune disease leading to hair loss from all or some parts of the body, usually the scalp.

Read the press release

News

5月. 2020 25 Innovative startups meet at EMERGENCE on April 9th, 2020

CEOs from cutting-edge life science startups share their real-life experience

詳しく読む
4月. 2020 02 EMERGENCE kicks off at Venture Café Tokyo on Feb 27, 2020

Experts discuss the future of the life science ecosystem in Japan from different perspectives

詳しく読む